Global Human Recombinant Insulin Market – Industry Insights
Insulin’s discovery is regarded as amongst the most vital events within history of treatment of diabetes. Moreover, major developments in the technology of human insulin are the human insulin analogue synthesis through recombinant technology. Presently, delivery system of human insulin available for insulin’s administration include jet injections, insulin pumps, pens, and insulin syringes. Major players are engaged on development of recombinant human insulin rather than animal-based insulin, due to rising demand of human insulin for diabetes treatment. Human recombinant insulin consists a faster action onset and lesser immunogenicity as compared with beef or pork insulin. Presently the human recombinant insulin is receiving significant traction along with the advancement of human insulin’s biosimilar analogue.
Get PDF Brochure with COVID19 Impact Analysis @ https://www.coherentmarketinsights.com/insight/request-pdf/1797
As per the 2016 report by Addressing the Challenge and Constraints of Insulin Sources and Supply (ACCISS): the market of insulin such as human recombinant insulin greatly contributes over 40 local companies, largely with local markets besides the three largest manufactures of global insulin: Novo Nordisk A/S, Eli Lilly and Company, and Sanofi S.A. Moreover, various manufacturers provide recombinant analog of the insulin-like human growth factor which has been particularly engineered for industrial cell culture market and research, offering a consistent, reliable, and compliant alternative for recombinant insulin. The manufacturers include: Thermo Fisher Scientific, Inc., Merck KGaA, among others. Such manufacturers offers products of recombinant human insulin analogue as the raw material or mixed with custom formulations of media for applications of commercial bio-manufacturing and process development at small-scale. Introduction of biosimilar along with other products of insulin and research of products for recombinant insulin is expected to propel the global human recombinant insulin market growth over the forecast period.
Furthermore, rising population of diabetes, globally along with rising R&D activities through various private and government organizations in development of human insulin is expected to drive the global human recombinant insulin market growth in the near future.
The global human recombinant insulin market accounted for US$ 27.4 billion in 2018, and is projected to exhibit a 7.2% CAGR over the forecast period (2018 – 2026).
Global Human Recombinant Insulin Market – Dynamics
Increasing Investment in Diabetes Research Activities is expected to boost the Growth of Human Recombinant Insulin Market
Several private and government research organizations are focused on activities of R&D to develop advanced treatments in diabetes-care for increasing the human insulin’s effectiveness, reducing diabetes burden, along with minimizing the threat of disorders associated with diabetes including diabetes-associated blindness, heart attacks, kidney disease, limb loss, or strokes. For instance, the American Diabetes Association (ADA) funded US$ 807.4 Mn in over 4,700 projects for diabetes research from 1952 to 2017. As per the 2017 review by ADA, ADA invested over US$ 37.4 Mn for the diabetes research in 2017, along with supporting 371 research projects related to diabetes. The European Foundation for the Study of Diabetes (EFSD), a European Association for the Study of Diabetes’ (EASD) division, offers funding initiatives in every area of the diabetes research. The EFSD aims at accelerating and supporting research within the diabetes field for introducing innovative portfolio of diabetic management.
Biocon Limited, a biopharmaceutical firm based in India, in September 2017, received funding by the Juvenile Diabetes Research Foundation (JDRF) for studying Tregopil, a candidate of oral insulin drug, for evaluating the tolerability and safety in people having diabetes of type 1. The collaboration among JDRF and Biocon is an aspect of Industry Discovery and Development Partnership (IDDP) programme by JDRF, by which JDRF offers financial support for Biocon for accelerating research in diabetes management of type 1.
Increasing prevalence of diabetes is a key factor is expected to drive the global human recombinant insulin market growth in the near future. For instance, as per the World Health Organization (WHO), in 2016, over 422 Mn adults have diabetes. A major surge in type 2 diabetes prevalence during the past decade is majorly attributed to rising incidence of obesity. As per the International Diabetes Federation (IDF) Atlas, in 2017, the global diabetes burden is affecting over 425 million populace, from which 33% are aged 65 years and above. Furthermore, the populace of diabetic people may increase to 629 Mn in 2045. Moreover, 352 Mn people having impaired tolerance of glucose are more likely to develop diabetes. Continuous rise in diabetes’ incidence rate, due to unhealthy lifestyles, obesity, binge eating, physical inactivity, along with insulin resistivity in global populace is further expected to boost the global human recombinant insulin market growth over the forecast period.
However, insulin’s high cost is expected to restrain the global human recombinant insulin market growth in the near future, as people from middle and low income countries cannot afford it. As per the May 2018 report by Pharmaceutical Care Management Association (PCMA), insulin’s prices have surged over 10-times from 1985 and the prices have projected significant rise over the past decade (2008 to 2018). As per the PCMA, Humulin/Novolin prices have raised from over US$ 25/prescription (1985) to over US$ 300 (2016). Moreover, long-acting insulin prices have surged from over US$ 100/prescription (2007) to over US$ 400 (2016).
Major players functioning in global human recombinant insulin market are Novo Nordisk A/S, Sanofi S.A., Eli Lilly and Company, Julphar Gulf Pharmaceutical Industries, Bioton S.A., Biocon Limited, Gan & Lee Pharmaceuticals, Ltd., Wanbang Biopharmaceuticals Co., Ltd., Zhuhai United Laboratories Co., Ltd., Dongbao Enterprise Group Co., Ltd., and others.
Purchase This Premium Report Here With Discounted Price (Flat US $2000 Off) – https://www.coherentmarketinsights.com/promo/buynow/1797
Reasons to Purchase this Report
• Current and future of global Human Recombinant Insulin market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027